Showing 2951-2960 of 3039 results for "".
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disordershttps://modernod.com/news/retipharma-secures-funding-to-develop-treatments-of-degenerative-eye-disorders/2479680/RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds usi
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post
- New Data from Johnson & Johnson Vision Highlights the Need and Potential Standards for Evidence-Based Decision-Making in Myopiahttps://modernod.com/news/new-data-from-johnson-johnson-vision-highlights-the-need-and-potential-standards-for-evidence-based-decision-making-in-myopia/2479698/Johnson & Johnson Vision announced that Noel A Brennan, PhD, the company’s Global Platform Lead for Myopia Control, will present data on myopia progression and investigational methods to control it at the 2018 American Academy of Optometry Annual Meeting, held November 7-10 in San Antonio, Te
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- Oxurion Supporting Prevent Blindness Sight-Saving Programs for Those with Diabeteshttps://modernod.com/news/oxurion-supporting-prevent-blindness-sight-saving-programs-for-those-with-diabetes/2479709/To help support the fight against vision loss and blindness due to diabetes, Oxurion has partnered with Prevent Blindness. During the Diabetic Eye Disease Awareness Month in November, Oxurion will help Prevent Blindness promote awareness and education of the damaging effects that diabetes may hav
- AAO: Unapproved Therapies Cause Significantly More Patient Injuries Than Reported by Cell Therapy Clinicshttps://modernod.com/news/aao-unapproved-therapies-cause-significantly-more-patient-injuries-than-reported-by-cell-therapy-clinics/2479716/A team of ophthalmologists went looking for scientific evidence in support of commercially available “cell therapy” for eye diseases. Not only did they find virtually none, they discovered a growing number of patients are being irreparably harmed by unapproved cell therapies, accordin
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th
- Evidence Mounts That an Eye Scan May Detect Early Alzheimer’s Diseasehttps://modernod.com/news/evidence-mounts-that-an-eye-scan-may-detect-early-alzheimers-disease/2479725/Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer’s disease in a matter of seconds. The researchers show that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer’s. Even patients who have a family histo
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi